Longitudinal Studies of Zanubrutinib: Safety and Durability of Response
Over the last few years, the treatment of B-cell malignancies has undergone significant changes, with increased attention being given to treatments tailored to disease-specific molecular pathways. Today, the development of targeted therapy and disease management for the long term is increasingly part of the approach to evaluating conditions like CLL, mantle cell lymphoma, and Waldenström […]
Longitudinal Studies of Zanubrutinib: Safety and Durability of Response Read More »










